It confirmed what we were seeing clinically that stopping without a structured plan puts most patients at significant risk of regaining the majority of what they worked to lose
Alprostadil's risks are predominantly local (injection site pain, priapism, fibrosis) while PT-141's risks are predominantly systemic (nausea, BP changes)
Our providers listen first, then help you find a path that works, whether thats injectable GLP-1s now or oral options as they become available through our programs
In recent years, glucagon-like peptide-1 receptor analogues (GLP-1 RAs) has revolutionised the treatment of T2D, as they have shown remarkable efficacy in reducing blood glucose levels while promoting substantial weight loss and weight maintenance, allowing for improved disease management (7, 8)
Delayed treatment with 4-methylpyrazole protects against acetaminophen hepatotoxicity in mice by inhibition of c-jun n-terminal kinase
J Ren Nutr